Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Genentech’s Perjeta Clears FDA Despite Unresolved Manufacturing Issues

Jun 18 2012

• By Sue Sutter

Related Content

<i>Avastin</i>’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?

Jul 04 2011

User Fee Conference Cmte. Could Be Relatively Messy After Clean Floor Votes

Jun 04 2012

With <em>Perjeta</em>, The Cost Of HER2 Breast Cancer Therapy Goes Up

Jun 18 2012

<em>Perjeta</em> Approval Is A Post-Marketing Affair For FDA, Genentech

Jun 18 2012

Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

Nov 21 2011

Related Companies

Genentech, Inc.

Additional Topics

United States Quality Post Market Regulation & Studies Manufacturing BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window